Share ownership GeNeuro SA

GNRO

CH0308403085

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-01-19 am EST			5-day change	1st Jan Change
0.0300 ^EUR	-6.83%		+7.14%	-4.46%

25-10-15	GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report	CI
25-10-15	Geneuro SA postpones publication of half-yearly financial report	RE

Share class: GeNeuro SA

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	24,999,028	12,852,217 ( 51.41 %)	164,739 ( 0.659 %)	51.41 %

Major shareholders: GeNeuro SA

Name	Equities	%	Valuation
Eclosion2 SA 19.32 %	5,750,108	19.32 %	212 064 €
Clay Asset Management SAS 0.2887 %	85,917	0.2887 %	3 169 €

Breakdown by shareholder type

Other	19.32%
Institutional	0.29%
Unknown	80.39%

Based on 1000 largest holdings

Geographical origin of shareholders

Switzerland	19.32%
France	0.29%

Based on 1000 largest holdings

GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.

Employees

Sector

Biotechnology & Medical Research

Calendar

Apr. 05 - Q4 2025 Earnings Release (Projected)

More about the company